New Analyses from FIBRONEER™ Trials Suggest Survival Benefit with Nerandomilast in IPF and PPF

Data ReadoutpositivenerandomilastPositive

AI Analysis

Summary

Boehringer Ingelheim's nerandomilast, an oral preferential PDE4B inhibitor, showed positive long-term survival modeling results predicting up to 5.4 years survival extension in adults with idiopathic and progressive pulmonary fibrosis based on FIBRONEER trial analyses.

Clinical Trial Data

Outcome Details

Long-term survival modeling predicts nerandomilast could extend survival by up to 5.4 years in adults with IPF and PPF

Importance:6/10

Sentiment:

0.75

pulmonary fibrosisPDE4B inhibitorsurvival benefitlong-term modeling

Related Companies

$INTI

Read the original article

Published by Drugs.com Clinical Trial Results on June 18, 2026 10:07 AM

Read Original